NCT00372476已完成4 期
Open-label Trial of Imatinib in Combination With Vinorelbine for Patients With Advanced Breast Carcinoma: ICON
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Imatinib + Vinorelbine
Experimental
干预措施: Imatinib and Vinorelbine (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: at least 28 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinNonsquamous Nonsmall Cell Neoplasm of LungMalignant Pleural MesotheliomaNCT02049060Armando Santoro, MD31
已完成
1 期
A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerGastric CancerNCT02252913Hutchison Medipharma Limited25
已完成
2 期
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenPhiladelphia ChromosomeAcute Lymphoblastic LeukemiaNCT00287105Rennes University Hospital49
终止
1 期
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLALK+ Anaplastic Large Cell LymphomaNCT02462538Arbeitsgemeinschaft medikamentoese Tumortherapie3
终止
不适用
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCResistant CancerHepatocellular CarcinomaLiver CancerNCT05718882RenJi Hospital5